Log in

Relevant bibliographies by topics / Cancer-On-Chip / Journal articles

To see the other types of publications on this topic, follow the link: Cancer-On-Chip.

Journal articles on the topic 'Cancer-On-Chip'

Author: Grafiati

Published: 8 June 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cancer-On-Chip.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Torisawa, Yu-suke, Yuta Mishima, and Shin Kaneko. "Developing thymus-on-a-chip and cancer-on-a-chip for cancer immunotherapy." Impact 2019, no. 2 (2019): 33–35. http://dx.doi.org/10.21820/23987073.2019.2.33.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Zhang, Xiaojun, Mazharul Karim, Md Mahedi Hasan, et al. "Cancer-on-a-Chip: Models for Studying Metastasis." Cancers 14, no. 3 (2022): 648. http://dx.doi.org/10.3390/cancers14030648.

Full text

Abstract:

The microfluidic-based cancer-on-a-chip models work as a powerful tool to study the tumor microenvironment and its role in metastasis. The models recapitulate and systematically simplify the in vitro tumor microenvironment. This enables the study of a metastatic process in unprecedented detail. This review examines the development of cancer-on-a-chip microfluidic platforms at the invasion/intravasation, extravasation, and angiogenesis steps over the last three years. The on-chip modeling of mechanical cues involved in the metastasis cascade are also discussed. Finally, the popular design of mi

APA, Harvard, Vancouver, ISO, and other styles

3

Komen, Job, Sanne M. van Neerven, Elsbeth G. B. M. Bossink, et al. "The Effect of Dynamic, In Vivo-like Oxaliplatin on HCT116 Spheroids in a Cancer-on-Chip Model Is Representative of the Response in Xenografts." Micromachines 13, no. 5 (2022): 739. http://dx.doi.org/10.3390/mi13050739.

Full text

Abstract:

The cancer xenograft model in which human cancer cells are implanted in a mouse is one of the most used preclinical models to test the efficacy of novel cancer drugs. However, the model is imperfect; animal models are ethically burdened, and the imperfect efficacy predictions contribute to high clinical attrition of novel drugs. If microfluidic cancer-on-chip models could recapitulate key elements of the xenograft model, then these models could substitute the xenograft model and subsequently surpass the xenograft model by reducing variation, increasing sensitivity and scale, and adding human f

APA, Harvard, Vancouver, ISO, and other styles

4

Lin, Tianxiu. "Organ-on-a-Chip Models for Pancreatic Cancer Research." International Journal of Sciences Volume 9, no. 2020-02 (2020): 49–56. https://doi.org/10.5281/zenodo.3980037.

Full text

Abstract:

Pancreatic cancer is the one of lowest survival rate cancer among all kinds of cancer. This is because its early syndromes are very different from other fatal diseases. Although with the development of the detection and management, more than 96% of the patients cannot live more than 5 years after diagnosis. Survival rate is low for those with malignant disease in the pancreas, because surgical resection at present may cut off the only chance of the cure. Unfortunately, 80–85% of patients are present with advanced unresectable pathology. Furthermore, pancreatic cancer responds poorly to most ch

APA, Harvard, Vancouver, ISO, and other styles

5

Lee, I.-Chi. "Cancer-on-a-chip for Drug Screening." Current Pharmaceutical Design 24, no. 45 (2019): 5407–18. http://dx.doi.org/10.2174/1381612825666190206235233.

Full text

Abstract:

: The oncology pharmaceutical research spent a shocking amount of money on target validation and drug optimization in preclinical models because many oncology drugs fail during clinical trial phase III. One of the most important reasons for oncology drug failures in clinical trials may due to the poor predictive tool of existing preclinical models. Therefore, in cancer research and personalized medicine field, it is critical to improve the effectiveness of preclinical predictions of the drug response of patients to therapies and to reduce costly failures in clinical trials. Three dimensional (

APA, Harvard, Vancouver, ISO, and other styles

6

Hao, Hsu-Chao, and Da-Jeng Yao. "Detection of Cancer Cells on a Chip." Current Topics in Medicinal Chemistry 15, no. 15 (2015): 1543–50. http://dx.doi.org/10.2174/1568026615666150414150950.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Elmusrati, Mohammed, and Nureddin Ashammakhi. "Cancer-on-a-Chip and Artificial Intelligence." Journal of Craniofacial Surgery 29, no. 7 (2018): 1682–83. http://dx.doi.org/10.1097/scs.0000000000004703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Reed, Sarah C., Chad Potts, P. Brent Ferrell, and Ben H. Park. "Abstract 1210: Modeling clonal hematopoiesis of indeterminate potential (CHIP) in solid tumors: genotype-specific effects on tumor growth and immune microenvironment." Cancer Research 85, no. 8_Supplement_1 (2025): 1210. https://doi.org/10.1158/1538-7445.am2025-1210.

Full text

Abstract:

Abstract Clonal Hematopoiesis of Indeterminate Potential (CHIP) is characterized by expanded blood cell clones containing somatic mutations in leukemia-associated genes in patients without hematologic malignancies. CHIP incidence increases with age, and it is primarily associated with an increased risk of transformation to myeloid neoplasms and cardiovascular disease. Growing evidence indicates that CHIP is associated with aberrant inflammatory signaling, and retrospective analyses have revealed increased risk or poor outcomes in a wide range of diseases. We hypothesized that CHIP alters the i

APA, Harvard, Vancouver, ISO, and other styles

9

Zuchowska, Agnieszka, and Sandra Skorupska. "Multi-organ-on-chip approach in cancer research." Organs-on-a-Chip 4 (December 2022): 100014. http://dx.doi.org/10.1016/j.ooc.2021.100014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Fey, M. F. "The impact of chip technology on cancer medicine." Annals of Oncology 13 (October 2002): 109–13. http://dx.doi.org/10.1093/annonc/mdf647.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Sabour, Andrew F., Seung-min Park, Jun Ho Son, and Luke P. Lee. "An On-Chip Pcr Approach Enabling Cancer Diagnosis." Biophysical Journal 106, no. 2 (2014): 618a. http://dx.doi.org/10.1016/j.bpj.2013.11.3420.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Liu, Qiang, Tian Zhao, Xianning Wang, Zhongyao Chen, Yawei Hu, and Xiaofang Chen. "In Situ Vitrification of Lung Cancer Organoids on a Microwell Array." Micromachines 12, no. 6 (2021): 624. http://dx.doi.org/10.3390/mi12060624.

Full text

Abstract:

Three-dimensional cultured patient-derived cancer organoids (PDOs) represent a powerful tool for anti-cancer drug development due to their similarity to the in vivo tumor tissues. However, the culture and manipulation of PDOs is more difficult than 2D cultured cell lines due to the presence of the culture matrix and the 3D feature of the organoids. In our other study, we established a method for lung cancer organoid (LCO)-based drug sensitivity tests on the superhydrophobic microwell array chip (SMAR-chip). Here, we describe a novel in situ cryopreservation technology on the SMAR-chip to prese

APA, Harvard, Vancouver, ISO, and other styles

13

Bērziņa, Santa, Alexandra Harrison, Valérie Taly, and Wenjin Xiao. "Technological Advances in Tumor-On-Chip Technology: From Bench to Bedside." Cancers 13, no. 16 (2021): 4192. http://dx.doi.org/10.3390/cancers13164192.

Full text

Abstract:

Tumor-on-chip technology has cemented its importance as an in vitro tumor model for cancer research. Its ability to recapitulate different elements of the in vivo tumor microenvironment makes it promising for translational medicine, with potential application in enabling personalized anti-cancer therapies. Here, we provide an overview of the current technological advances for tumor-on-chip generation. To further elevate the functionalities of the technology, these approaches need to be coupled with effective analysis tools. This aspect of tumor-on-chip technology is often neglected in the curr

APA, Harvard, Vancouver, ISO, and other styles

14

MASUDA, Taisuke, Miyako NIIMI, Hayao NAKANISHI, and Fumihito ARAI. "7B21 On-chip Cancer Diagnosis for Early Recognition of Gastric Cancer." Proceedings of the Bioengineering Conference Annual Meeting of BED/JSME 2012.24 (2012): _7B21–1_—_7B21–2_. http://dx.doi.org/10.1299/jsmebio.2012.24._7b21-1_.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Gambari, Roberto, Monica Borgatti, Luigi Altomare, et al. "Applications to Cancer Research of “Lab-on-a-chip” Devices Based on Dielectrophoresis (DEP)." Technology in Cancer Research & Treatment 2, no. 1 (2003): 31–39. http://dx.doi.org/10.1177/153303460300200105.

Full text

Abstract:

The recent development of advanced analytical and bioseparation methodologies based on microarrays and biosensors is one of the strategic objectives of the so-called post-genomic. In this field, the development of microfabricated devices could bring new opportunities in several application fields, such as predictive oncology, diagnostics and anti-tumor drug research. The so called “Laboratory-on-a-chip technology”, involving miniaturisation of analytical procedures, is expected to enable highly complex laboratory testing to move from the central laboratory into non-laboratory settings. The mai

APA, Harvard, Vancouver, ISO, and other styles

16

Regmi, Sagar, Chetan Poudel, Rameshwar Adhikari, and Kathy Qian Luo. "Applications of Microfluidics and Organ-on-a-Chip in Cancer Research." Biosensors 12, no. 7 (2022): 459. http://dx.doi.org/10.3390/bios12070459.

Full text

Abstract:

Taking the life of nearly 10 million people annually, cancer has become one of the major causes of mortality worldwide and a hot topic for researchers to find innovative approaches to demystify the disease and drug development. Having its root lying in microelectronics, microfluidics seems to hold great potential to explore our limited knowledge in the field of oncology. It offers numerous advantages such as a low sample volume, minimal cost, parallelization, and portability and has been advanced in the field of molecular biology and chemical synthesis. The platform has been proved to be valua

APA, Harvard, Vancouver, ISO, and other styles

17

Desai, Pinkal, Samuel Handelman, Alan Wu, et al. "Antecedent Clonal Hematopoesis and Risk of and Mortality after Solid and Hematological Malignancies: Analyses from the Women's Health Initiative Study." Blood 134, Supplement_1 (2019): 1199. http://dx.doi.org/10.1182/blood-2019-131862.

Full text

Abstract:

Background: Whole genome analyses of peripheral blood has demonstrated that acquired somatic mutations in peripheral blood also known as clonal hematopoiesis of indeterminate potential (CHIP) is present in up to 10% of individuals older than 60 years and associated with increased risk of cardiovascular mortality and hematologic malignancies (Jaiswal et al, Genovese et al, NEJM 2014). We have demonstrated that CHIP is associated specifically with increased risk of leukemia (Desai et al, Nat. Medicine 2018). CHIP has also been detected in 25% of individuals with concomitant advanced solid malign

APA, Harvard, Vancouver, ISO, and other styles

18

Tsai, Hsieh-Fu, Alen Trubelja, Amy Q. Shen, and Gang Bao. "Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment." Journal of The Royal Society Interface 14, no. 131 (2017): 20170137. http://dx.doi.org/10.1098/rsif.2017.0137.

Full text

Abstract:

Cancer remains one of the leading causes of death, albeit enormous efforts to cure the disease. To overcome the major challenges in cancer therapy, we need to have a better understanding of the tumour microenvironment (TME), as well as a more effective means to screen anti-cancer drug leads; both can be achieved using advanced technologies, including the emerging tumour-on-a-chip technology. Here, we review the recent development of the tumour-on-a-chip technology, which integrates microfluidics, microfabrication, tissue engineering and biomaterials research, and offers new opportunities for b

APA, Harvard, Vancouver, ISO, and other styles

19

Marturano-Kruik, Alessandro, Michele Maria Nava, Keith Yeager, et al. "Human bone perivascular niche-on-a-chip for studying metastatic colonization." Proceedings of the National Academy of Sciences 115, no. 6 (2018): 1256–61. http://dx.doi.org/10.1073/pnas.1714282115.

Full text

Abstract:

Eight out of 10 breast cancer patients die within 5 years after the primary tumor has spread to the bones. Tumor cells disseminated from the breast roam the vasculature, colonizing perivascular niches around blood capillaries. Slow flows support the niche maintenance by driving the oxygen, nutrients, and signaling factors from the blood into the interstitial tissue, while extracellular matrix, endothelial cells, and mesenchymal stem cells regulate metastatic homing. Here, we show the feasibility of developing a perfused bone perivascular niche-on-a-chip to investigate the progression and drug

APA, Harvard, Vancouver, ISO, and other styles

20

Lee, Jae-Sung, Sae-Wan Kim, Eun-Yoon Jang, et al. "Rapid and Sensitive Detection of Lung Cancer Biomarker Using Nanoporous Biosensor Based on Localized Surface Plasmon Resonance Coupled with Interferometry." Journal of Nanomaterials 2015 (2015): 1–11. http://dx.doi.org/10.1155/2015/183438.

Full text

Abstract:

We propose a nanobiosensor to evaluate a lung cancer-specific biomarker. The nanobiosensor is based on an anodic aluminum oxide (AAO) chip and functions on the principles of localized surface plasmon resonance (LSPR) and interferometry. The pore-depth of the fabricated nanoporous AAO chip was 1 µm and was obtained using a two-step electrochemical anodization process. The sensor chip is sensitive to the refractive index (RI) changes of the surrounding medium and also provides simple and label-free detection when specific antibodies are immobilized on the gold-deposited surface of the AAO chip.

APA, Harvard, Vancouver, ISO, and other styles

21

Ustun, Merve, Sajjad Rahmani Dabbagh, Irem Ilci, Tugba Bagci-Onder, and Savas Tasoglu. "Glioma-on-a-Chip Models." Micromachines 12, no. 5 (2021): 490. http://dx.doi.org/10.3390/mi12050490.

Full text

Abstract:

Glioma, as an aggressive type of cancer, accounts for virtually 80% of malignant brain tumors. Despite advances in therapeutic approaches, the long-term survival of glioma patients is poor (it is usually fatal within 12–14 months). Glioma-on-chip platforms, with continuous perfusion, mimic in vivo metabolic functions of cancer cells for analytical purposes. This offers an unprecedented opportunity for understanding the underlying reasons that arise glioma, determining the most effective radiotherapy approach, testing different drug combinations, and screening conceivable side effects of drugs

APA, Harvard, Vancouver, ISO, and other styles

22

Ngo, Huyen, Sarnai Amartumur, Van Thi Ai Tran, et al. "In Vitro Tumor Models on Chip and Integrated Microphysiological Analysis Platform (MAP) for Life Sciences and High-Throughput Drug Screening." Biosensors 13, no. 2 (2023): 231. http://dx.doi.org/10.3390/bios13020231.

Full text

Abstract:

The evolution of preclinical in vitro cancer models has led to the emergence of human cancer-on-chip or microphysiological analysis platforms (MAPs). Although it has numerous advantages compared to other models, cancer-on-chip technology still faces several challenges such as the complexity of the tumor microenvironment and integrating multiple organs to be widely accepted in cancer research and therapeutics. In this review, we highlight the advancements in cancer-on-chip technology in recapitulating the vital biological features of various cancer types and their applications in life sciences

APA, Harvard, Vancouver, ISO, and other styles

23

Barnao, Kara Marie, Aubrey K. Hubbard, Irenaeus Chan, et al. "Abstract 4916: Co-occurring clonal hematopoiesis in UK Biobank participants with prior cancer." Cancer Research 85, no. 8_Supplement_1 (2025): 4916. https://doi.org/10.1158/1538-7445.am2025-4916.

Full text

Abstract:

Abstract Clonal hematopoiesis (CH) describes the age-related clonal expansion of hematopoietic stem cells, driven by either acquired mutations in driver genes (referred to as clonal hematopoiesis of indeterminate potential (CHIP)), or by large-scale mosaic chromosomal alterations (mCAs). Evidence from previous studies indicate anti-cancer agents, such as chemotherapy and radiation therapy, may promote the expansion of clones with DNA damage response mutations (e.g., TP53, PPM1D, and CHEK2). However, the co-occurrence of CHIP and mCAs in participants with prior cancer has not been extensively c

APA, Harvard, Vancouver, ISO, and other styles

24

Liu, Yan, Qingzhen Yang, Hui Zhang, et al. "Construction of cancer-on-a-chip for drug screening." Drug Discovery Today 26, no. 8 (2021): 1875–90. http://dx.doi.org/10.1016/j.drudis.2021.03.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Lin, Tianxiu. "Organ-on-a-Chip Models for Pancreatic Cancer Research." International Journal of Sciences 9, no. 02 (2020): 49–56. http://dx.doi.org/10.18483/ijsci.2253.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

He, J. H., J. Reboud, H. Ji, L. Zhang, Y. Long, and C. Lee. "Biomicrofluidic lab-on-chip device for cancer cell detection." Applied Physics Letters 93, no. 22 (2008): 223905. http://dx.doi.org/10.1063/1.3040313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Lee, Esak, H.-H. Greco Song, and Christopher S. Chen. "Biomimetic on-a-chip platforms for studying cancer metastasis." Current Opinion in Chemical Engineering 11 (February 2016): 20–27. http://dx.doi.org/10.1016/j.coche.2015.12.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Özyurt, Canan, İnci Uludağ, Bahar İnce, and Mustafa Kemal Sezgintürk. "Lab-on-a-chip systems for cancer biomarker diagnosis." Journal of Pharmaceutical and Biomedical Analysis 226 (March 2023): 115266. http://dx.doi.org/10.1016/j.jpba.2023.115266.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

S. Rao, Roopa, Shankargouda Patil, and B. S. Ganavi. "Oral cancer-on-a-chip: A biomimicry to transform oral cancer research?" Journal of Medicine, Radiology, Pathology & Surgery 1, no. 2 (2015): 1–2. http://dx.doi.org/10.15713/ins.jmrps.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Holler, Albert E., Lukasz Gondek, Hua-Ling Tsai, et al. "Clonal hematopoiesis of indeterminate potential (CHIP) and association with response to bipolar androgen therapy (BAT)." Journal of Clinical Oncology 41, no. 16_suppl (2023): e17048-e17048. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e17048.

Full text

Abstract:

e17048 Background: CHIP, the expansion of hematopoietic cells carrying acquired somatic alterations associated with hematologic malignancies, is associated with increased inflammation, risk of heart disease, and poor outcomes. BAT, where testosterone levels are therapeutically manipulated between castrate levels to supraphysiologic levels, has been shown to be an effective therapy for some men with castration resistant prostate cancer. Clinical predictors of response are not established. We hypothesized that CHIP, would be negatively associated with clinical outcomes. Methods: Baseline periphe

APA, Harvard, Vancouver, ISO, and other styles

31

Ewell, Desiree J., Nita Vue, Sakib M. Moinuddin, Tanoy Sarkar, Fakhrul Ahsan, and Ruth L. Vinall. "Development of a Bladder Cancer-on-a-Chip Model to Assess Bladder Cancer Cell Invasiveness." Cancers 16, no. 15 (2024): 2657. http://dx.doi.org/10.3390/cancers16152657.

Full text

Abstract:

We have developed a bladder cancer-on-a-chip model which supports the 3D growth of cells and can be used to assess and quantify bladder cancer cell invasiveness in a physiologically appropriate environment. Three bladder cancer cell lines (T24, J82, and RT4) were resuspended in 50% Matrigel® and grown within a multi-channel organ-on-a-chip system. The ability of live cells to invade across into an adjacent 50% Matrigel®-only channel was assessed over a 2-day period. Cell lines isolated from patients with high-grade bladder cancer (T24 and J82) invaded across into the Matrigel®-only channel at

APA, Harvard, Vancouver, ISO, and other styles

32

Bretti, Gabriella, Adele De Ninno, Roberto Natalini, Daniele Peri, and Nicole Roselli. "Estimation Algorithm for a Hybrid PDE–ODE Model Inspired by Immunocompetent Cancer-on-Chip Experiment." Axioms 10, no. 4 (2021): 243. http://dx.doi.org/10.3390/axioms10040243.

Full text

Abstract:

The present work is motivated by the development of a mathematical model mimicking the mechanisms observed in lab-on-chip experiments, made to reproduce on microfluidic chips the in vivo reality. Here we consider the Cancer-on-Chip experiment where tumor cells are treated with chemotherapy drug and secrete chemical signals in the environment attracting multiple immune cell species. The in silico model here proposed goes towards the construction of a “digital twin” of the experimental immune cells in the chip environment to better understand the complex mechanisms of immunosurveillance. To this

APA, Harvard, Vancouver, ISO, and other styles

33

LI, CHIYU, WANG LI, CHUNYANG GENG, HAIJUN REN, XIAOHUI YU, and BO LIU. "MICROFLUIDIC CHIP FOR CANCER CELL DETECTION AND DIAGNOSIS." Journal of Mechanics in Medicine and Biology 18, no. 01 (2018): 1830001. http://dx.doi.org/10.1142/s0219519418300016.

Full text

Abstract:

Since cancer becomes the most deadly disease to our health, research on early detection on cancer cells is necessary for clinical treatment. The combination of microfluidic device with cell biology has shown a unique method for cancer cell research. In the present review, recent development on microfluidic chip for cancer cell detection and diagnosis will be addressed. Some typical microfluidic chips focussed on cancer cells and their advantages for different kinds of cancer cell detection and diagnosis will be listed, and the cell capture methods within the microfluidics will be simultaneousl

APA, Harvard, Vancouver, ISO, and other styles

34

Zhu, Luyao, Changmin Shao, Hanxu Chen, Zhuoyue Chen, and Yuanjin Zhao. "Hierarchical Hydrogels with Ordered Micro-Nano Structures for Cancer-on-a-Chip Construction." Research 2021 (December 26, 2021): 1–9. http://dx.doi.org/10.34133/2021/9845679.

Full text

Abstract:

In the drug therapy of tumor, efficient and stable drug screening platforms are required since the drug efficacy varies individually. Here, inspired by the microstructures of hepatic lobules, in which hepatocytes obtain nutrients from both capillary vessel and the central vein, we present a novel hierarchical hydrogel system with ordered micro-nano structure for liver cancer-on-a-chip construction and drug screening. The hierarchical hydrogel system was fabricated by using pregel to fill and replicate self-assembled colloidal crystal arrays and microcolumn array template. Due to the synergisti

APA, Harvard, Vancouver, ISO, and other styles

35

Ngan Ngo, Thi Kim, Cheng-Hsiang Kuo, and Ting-Yuan Tu. "Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies." Biomicrofluidics 17, no. 1 (2023): 011501. http://dx.doi.org/10.1063/5.0108792.

Full text

Abstract:

Despite several extraordinary improvements in cancer immunotherapy, its therapeutic effectiveness against many distinct cancer types remains mostly limited and requires further study. Different microfluidic-based cancer immunotherapy-on-a-chip (ITOC) systems have been developed to help researchers replicate the tumor microenvironment and immune system. Numerous microfluidic platforms can potentially be used to perform various on-chip activities related to early clinical cancer immunotherapy processes, such as improving immune checkpoint blockade therapy, studying immune cell dynamics, evaluati

APA, Harvard, Vancouver, ISO, and other styles

36

Flebbe, Hannah, Feda H. Hamdan, Vijayalakshmi Kari, et al. "Epigenome Mapping Identifies Tumor-Specific Gene Expression in Primary Rectal Cancer." Cancers 11, no. 8 (2019): 1142. http://dx.doi.org/10.3390/cancers11081142.

Full text

Abstract:

Epigenetic alterations play a central role in cancer development and progression. The acetylation of histone 3 at lysine 27 (H3K27ac) specifically marks active genes. While chromatin immunoprecipitation (ChIP) followed by next-generation sequencing (ChIP-seq) analyses are commonly performed in cell lines, only limited data are available from primary tumors. We therefore examined whether cancer-specific alterations in H3K27ac occupancy can be identified in primary rectal cancer. Tissue samples from primary rectal cancer and matched mucosa were obtained. ChIP-seq for H3K27ac was performed and di

APA, Harvard, Vancouver, ISO, and other styles

37

Pérez González, Ana, Clàudia Pellín Jou, Laura Palomo, et al. "Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients." Blood 142, Supplement 1 (2023): 5593. http://dx.doi.org/10.1182/blood-2023-189503.

Full text

Abstract:

INTRODUCTION Prevalence of CHIP in cancer patients (pts) is estimated at about 25%, its presence being associated with inferior outcomes and with increased risk of development of therapy-related myeloid neoplasms (TRMN). Despite the increased body of knowledge on cancer and CHIP, processes driving the selection of clones and their latter malignant transformation have not been fully elucidated. We hypothesized that CHIP in cancer pts might not only lead to TRMN but also affect the prognosis of the primary neoplasm and its treatment-related toxicity. Our study aims to describe the prevalence and

APA, Harvard, Vancouver, ISO, and other styles

38

Gillis, Nancy K., Markus Ball, Qing Zhang, et al. "Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly." Blood 128, no. 22 (2016): 295. http://dx.doi.org/10.1182/blood.v128.22.295.295.

Full text

Abstract:

Abstract Background Clonal hematopoiesis of indeterminate potential (CHIP) is an age-dependent genetic event occurring in as high as 10% of individuals over age 70. Although the clinical consequence of CHIP is not well understood, it is linked to an increased risk of primary hematologic malignancies and increased all-cause mortality. A recent study reported a higher prevalence (26%) of CHIP in patients with advanced cancers (Zehir A, ASCO abstract, 2016). However, the prevalence of CHIP in patients developing therapy-related myeloid neoplasms (T-MN) is unknown. We hypothesize that chemotherapy

APA, Harvard, Vancouver, ISO, and other styles

39

Tan, Jianfeng, Xindi Sun, Jianhua Zhang, et al. "Exploratory Evaluation of EGFR-Targeted Anti-Tumor Drugs for Lung Cancer Based on Lung-on-a-Chip." Biosensors 12, no. 8 (2022): 618. http://dx.doi.org/10.3390/bios12080618.

Full text

Abstract:

In this study, we used three-dimensional (3D) printing to prepare a template of a microfluidic chip from which a polydimethylsiloxane (PDMS)lung chip was successfully constructed. The upper and lower channels of the chip are separated by a microporous membrane. The upper channel is seeded with lung cancer cells, and the lower channel is seeded with vascular endothelial cells and continuously perfused with cell culture medium. This lung chip can simulate the microenvironment of lung tissue and realize the coculture of two kinds of cells at different levels. We used a two-dimensional (2D) well p

APA, Harvard, Vancouver, ISO, and other styles

40

Wang, Anqi, Yili Xu, Xin Sheng, et al. "Abstract 3508: Association between clonal hematopoiesis and risk of prostate cancer in a large sample of African ancestry men." Cancer Research 83, no. 7_Supplement (2023): 3508. http://dx.doi.org/10.1158/1538-7445.am2023-3508.

Full text

Abstract:

Abstract Clonal hematopoiesis of indeterminate potential (CHIP) has been associated with inflammation, which is a risk factor for cancer, including prostate cancer. We previously reported weak evidence of an association between CHIP and prostate cancer risk in men of European ancestry. However, little is known for African ancestry populations. We investigated the association of age-related CHIP with overall and aggressive prostate cancer risk in a large whole-exome sequencing study of 12,049 African ancestry men, including 7,176 prostate cancer cases (of which 3,283 had aggressive disease and

APA, Harvard, Vancouver, ISO, and other styles

41

Ngan Ngo, Thi Kim, and Ting-Yuan Tu. "Abstract 35: Hydrogel-based microwell chip for improved organoid culture and on-chip imaging." Cancer Research 85, no. 8_Supplement_1 (2025): 35. https://doi.org/10.1158/1538-7445.am2025-35.

Full text

Abstract:

Abstract Organoids have become essential tools for modeling complex biological systems, driving significant advancements in drug screening, cancer research, and regenerative medicine. However, traditional dome-shaped organoid culture methods come with notable limitations. These include variability in organoid size, structural heterogeneity, and difficulties in achieving high-resolution imaging due to overlapping positions and artifacts from the surrounding extracellular matrix (ECM). Such issues often hinder the reproducibility and precision of experimental outcomes, especially in long-term cu

APA, Harvard, Vancouver, ISO, and other styles

42

Guo, Jia, Tuotuo Gong, Beina Hui, Xu Zhao, and Jing Li. "Screening Tumor-Related Genes of Gallbladder Cancer Based on AR-Based Tumor Expression Profile Gene Chip." Contrast Media & Molecular Imaging 2022 (September 26, 2022): 1–11. http://dx.doi.org/10.1155/2022/8579279.

Full text

Abstract:

The rapid development of molecular biology and gene chip technology has produced a large amount of gene expression profile data. The main research in this article is to screen the tumor-related genes of gallbladder cancer based on AR-based tumor expression profile gene chip. First, convert the chip data into an expression matrix pattern that can be analyzed, and then standardize and normalize all the data. Run ReliefF, GA, and IReliefF-GA on the data set, record the size of the feature subset, and use the tenfold cross-validation method to obtain the classification accuracy, specificity, and s

APA, Harvard, Vancouver, ISO, and other styles

43

Duzagac, Fahriye, Gloria Saorin, Lorenzo Memeo, Vincenzo Canzonieri, and Flavio Rizzolio. "Microfluidic Organoids-on-a-Chip: Quantum Leap in Cancer Research." Cancers 13, no. 4 (2021): 737. http://dx.doi.org/10.3390/cancers13040737.

Full text

Abstract:

Organ-like cell clusters, so-called organoids, which exhibit self-organized and similar organ functionality as the tissue of origin, have provided a whole new level of bioinspiration for ex vivo systems. Microfluidic organoid or organs-on-a-chip platforms are a new group of micro-engineered promising models that recapitulate 3D tissue structure and physiology and combines several advantages of current in vivo and in vitro models. Microfluidics technology is used in numerous applications since it allows us to control and manipulate fluid flows with a high degree of accuracy. This system is an e

APA, Harvard, Vancouver, ISO, and other styles

44

Marshall, Catherine Handy, Lukasz Gondek, Elizabeth Mauer, Calvin Y. Chao, Jun Luo, and Emmanuel S. Antonarakis. "Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers." Journal of Clinical Oncology 41, no. 16_suppl (2023): 10522. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.10522.

Full text

Abstract:

10522 Background: The contribution of germline genetics on the emergence of CHIP in patients with solid tumor malignancies is not well understood. We hypothesized that those with germline (g) alterations in homologous recombination repair genes (gHRR) and BRCA-associated cancers (breast, ovarian, prostate, pancreas) would have different rates of CHIP than those without. Methods: We analyzed a large real-world Tempus multimodal database of paired germline and somatic DNA sequencing results. CHIP was calculated based on the presence of pathogenic or likely pathogenic alterations in any one of 16

APA, Harvard, Vancouver, ISO, and other styles

45

Park, Jeongmin, GangPyo Ryu, Daniel Nachun, et al. "Abstract 2277: Understanding the impact of clonal hematopoiesis on multiple myeloma: Insights from exosomal RNA analysis and survival analysis." Cancer Research 84, no. 6_Supplement (2024): 2277. http://dx.doi.org/10.1158/1538-7445.am2024-2277.

Full text

Abstract:

Abstract Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a trait characterized by the accumulation of somatic mutations in hematopoietic stem cells in certain adults. It has been observed that the presence of CHIP can have significant implications for the development and prognosis of various blood cancers. Multiple myeloma (MM), a cancer involving the abnormal proliferation of malignant plasma cells in the bone marrow, is one such condition. Exosomes, a type of extracellular vesicles, play a role in cell communication by carrying information between cells. Analysis of UK Biobank data

APA, Harvard, Vancouver, ISO, and other styles

46

Yu, Xiaolei, Bingrui Wang, Nangang Zhang, et al. "Capture and Release of Cancer Cells by Combining On-Chip Purification and Off-Chip Enzymatic Treatment." ACS Applied Materials & Interfaces 7, no. 43 (2015): 24001–7. http://dx.doi.org/10.1021/acsami.5b06791.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Caballero, D., S. Kaushik, V. M. Correlo, J. M. Oliveira, R. L. Reis, and S. C. Kundu. "Organ-on-chip models of cancer metastasis for future personalized medicine: From chip to the patient." Biomaterials 149 (December 2017): 98–115. http://dx.doi.org/10.1016/j.biomaterials.2017.10.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Ferrone, Christina K., Mackenzie Blydt-Hansen, and Michael J. Rauh. "Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease." International Journal of Molecular Sciences 21, no. 2 (2020): 626. http://dx.doi.org/10.3390/ijms21020626.

Full text

Abstract:

Acquired, inactivating mutations in Tet methylcytosine dioxygenase 2 (TET2) are detected in peripheral blood cells of a remarkable 5%–10% of adults greater than 65 years of age. They impart a hematopoietic stem cell advantage and resultant clonal hematopoiesis of indeterminate potential (CHIP) with skewed myelomonocytic differentiation. CHIP is associated with an overall increased risk of transformation to a hematological malignancy, especially myeloproliferative and myelodysplastic neoplasms (MPN, MDS) and acute myeloid leukemia (AML), of approximately 0.5% to 1% per year. However, it is beco

APA, Harvard, Vancouver, ISO, and other styles

49

Conces, Madison, Ying Ni, Peter Bazeley, Bhumika Patel, Pauline Funchain, and Hetty E. Carraway. "Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies." Journal of Clinical Oncology 37, no. 15_suppl (2019): 1507. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1507.

Full text

Abstract:

1507 Background: CHIP predisposes to a higher risk of developing hematological malignancies and cardiac events. Multiple germline mutations have been recognized as contributing to CHIP, most notably ASXL1, DNMT3A, and TET2. The frequency of CHIP mutations in solid tumor malignancies (STM) is unknown. We report the frequency and incidence of CHIP mutations in adult patients (pts) with STM. Methods: Data from 880 pts with STM who underwent next generation sequencing (NGS) at Foundation One from 2013-2017 was collected. This excluded two pts with known primary hematological malignancies who were

APA, Harvard, Vancouver, ISO, and other styles

50

Vaquero-Sedas, María I., and Miguel A. Vega-Palas. "Assessing the Epigenetic Status of Human Telomeres." Cells 8, no. 9 (2019): 1050. http://dx.doi.org/10.3390/cells8091050.

Full text

Abstract:

The epigenetic modifications of human telomeres play a relevant role in telomere functions and cell proliferation. Therefore, their study is becoming an issue of major interest. These epigenetic modifications are usually analyzed by microscopy or by chromatin immunoprecipitation (ChIP). However, these analyses could be challenged by subtelomeres and/or interstitial telomeric sequences (ITSs). Whereas telomeres and subtelomeres cannot be differentiated by microscopy techniques, telomeres and ITSs might not be differentiated in ChIP analyses. In addition, ChIP analyses of telomeres should be pro

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!